Cell therapy can cure cancer.
Bring it to life.

Austrian Life Science Day 2023

Sarcura

1

Curing Cancer From Within: The Promise of Cell Therapy

- "Living drugs" with transformative impact on oncology
- spectacular efficacy in blood cancers, with remission rates upward of 90%
- most therapies use patient derived cells as starting materials – 1 batch for 1 patient

clinical trials CAR-T therapies (CAGR 36%)



Source: CRI Analytics, June 2022

How does it work?



2

2

Cell Therapy Manufacturing Challenges

Quality

- High lot to lot variability
- Open, manual process
- Uncontrolled unit operations

10% of the batches don't deliver a final product due to manufacturing failure [1]

Quantity

- Labour & time intensive
- Long process time (>8 days)
- Manual process documentation

"1.000 doses a year, there is a need for 100 trained employees and 20 cleanroom suits"

Cost

- Small unit operations with poor yield
- High cost of goods sold

Manufacturing costs of > 170.000 $ per dose [2]

3

3

How to scale manufacturing capacity 100x ?

A typical industrial, manual CAR-T manufacturing setup today (image: Cytiva).



1.000 doses



100.000 doses

4

4

Sarcura's Approach

Automation | Integration | Miniaturization | Modularity

Using semiconductor technology to bring processing and real time control to cellular level.

Current status: Individual devices for each step



Functional modules perform unit operations in a closed cartridge

5

Team

Founder

Daniela Buchmayr, MBA
- Co-Founder & CEO
- 14 yrs corporate experience in the Biopharmaceutical Industry in business & market development, innovation management at

PALL Parker GEA

DI Dr. Martin Fischlechner
- Co-Founder, Director Technical Development
- 12 yrs academic research in microfluidic design and biological assay development in UK (Cambridge, Southampton) and AUT

Dr. Erwin Gorjup
- Co-Founder, Director Application Development
- Stem cell biologist with 11 yrs experience in research and industrial development at

Fraunhofer UK GEA

Advisory Board

"The company is well positioned to execute on the tremendous potential of their platform and help realize the promise of cell therapies by bringing curative treatments to oncology patients and beyond worldwide"

Nicoletta Loggia, Ph.D.
- CTO @ Orchard Therapeutics
- Former Global Head of Cell & Gene Therapy @ Novartis

"Sarcura's technology holds the potential to finally provide a mean for scientists and developers to identify, get to, and engineer the right cell"

Fabio Fachin, Ph.D.
- Head of Cell Therapy Process Development and Automation @ Takeda
- Former VP of Cell Therapy Engineering and Manufacturing @ Torque Therapeutics

… and an amazing team of 18 multidisciplinary, international experts!

6